Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119:6198–208.
Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014;28:143–53.
Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31:1855–68.
Walter RB. Investigational CD33-targeted therapeutics for acute myeloid leukemia. Expert Opin Investig Drugs. 2018;27:339–48.
Brinkman-Van der Linden EC, Angata T, Reynolds SA, Powell LD, Hedrick SM, Varki A. CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice. Mol Cell Biol. 2003;23:4199–206.
Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. 2018;173:1439–53.e19.
Jiang F, Doudna JA. CRISPR-Cas9 structures and mechanisms. Annu Rev Biophys. 2017;46:505–29.
Lucas D, O’Leary HA, Ebert BL, Cowan CA, Tremblay CS. Utility of CRISPR/Cas9 systems in hematology research. Exp Hematol. 2017;54:1–3.
Gundry MC, Dever DP, Yudovich D, Bauer DE, Haas S, Wilkinson AC, et al. Technical considerations for the use of CRISPR/Cas9 in hematology research. Exp Hematol. 2017;54:4–11.
Collins PJ, Hale CM, Xu H. Edited course of biomedical research: leaping forward with CRISPR. Pharmacol Res. 2017;125(Pt B):258–65.
Laszlo GS, Harrington KH, Gudgeon CJ, Beddoe ME, Fitzgibbon MP, Ries RE, et al. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia. Oncotarget. 2016;7:43281–94.
Humbert O, Peterson CW, Norgaard ZK, Radtke S, Kiem HP. A nonhuman primate transplantation model to evaluate hematopoietic stem cell gene editing strategies for beta-hemoglobinopathies. Mol Ther Methods Clin Dev. 2018;8:75–86.
Correnti CE, Laszlo GS, de van der Schueren WJ, Godwin CD, Bandaranayake A, Busch MA, et al. Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia. 2018;32:1239–43.
Haworth KG, Ironside C, Norgaard ZK, Obenza WM, Adair JE, Kiem HP. In vivo murine-matured human CD3( + ) cells as a preclinical model for T cell-based immunotherapies. Mol Ther Methods Clin Dev. 2017;6:17–30.
Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671–5.
We thank Dr. Colin E. Correnti and the Molecular Design and Therapeutics core facility team (Fred Hutchinson Cancer Research Center) for the generation of AMG 330. We also thank Helen Crawford for help preparing and formatting this manuscript, and Jerry Chen for general mouse colony maintenance. Research reported in this publication was supported by the Leukemia & Lymphoma Society (Translational Research Program, grant 6489-16). RBW is a Leukemia & Lymphoma Society Scholar in Clinical Research. H-PK is a Markey Molecular Medicine Investigator and received support as the inaugural recipient of the José Carreras/E. Donnall Thomas Endowed Chair for Cancer Research and the Fred Hutchinson Cancer Research Center Endowed Chair for Cell and Gene Therapy.
Conflict of interest
RBW has received laboratory research grants and/or clinical trial support from Actinium Pharmaceuticals, Inc, Amgen Inc., Amphivena Therapeutics, Inc., Covagen AG, and Seattle Genetics, Inc.; has ownership interests with Amphivena Therapeutics, Inc.; and is (or has been) a consultant to Amphivena Therapeutics, Inc., Boehringer Ingelheim Pharma GmbH & Co. KG, Covagen AG, Pfizer, Inc., and Seattle Genetics, Inc. H-PK is a consultant for Rocket Pharma and Homology Medicines. The other authors declare that they have no conflict of interest.
Electronic supplementary material
About this article
Cite this article
Humbert, O., Laszlo, G.S., Sichel, S. et al. Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2. Leukemia 33, 762–808 (2019). https://doi.org/10.1038/s41375-018-0277-8
Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy
Current Opinion in Hematology (2020)
In Vivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model
Molecular Therapy (2020)
Biochemical Pharmacology (2020)